亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study

医学 回顾性队列研究 内科学 优势比 置信区间 气胸 人口 联合疗法 肺栓塞 外科 环境卫生
作者
Murat Bektaş,Mustafa Ay,Muhammed Hamdi Uyar,Muhammed İkbal Kılıç
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:129: 111586-111586 被引量:1
标识
DOI:10.1016/j.intimp.2024.111586
摘要

In this study, we aimed to evaluate the safety and efficacy of combination treatment of high-dose intravenous anakinra and baricitinib in patients with critically ill COVID-19. This retrospective observational study was conducted in a tertiary center with diagnosis of COVID-19 patients. Study population consisted of patients with positive polymerase chain reaction and computer tomography findings compatible with COVID-19 as well as critical illness. Data of 15 patients in combination group and 43 patients in control group were evaluated and included into the study. Overall mortality was 46.7 % (n = 7) in combination arm and 69.8 % (n = 30) in control group although it was not statistically significant (p = 0.1). Similarly, need of intubation was also lower in combination arm (46.7 %) compared to control group (69.8 %), it was not significantly different (p = 0.1). ICU admission was significantly lower in combination (46.7 %, n = 7) arm than control group (76.7 %, n = 33) (p = 0.03, Odds ratio [OR]:4.7). Development of severe infection (20 %, n = 3 vs 25 %, n = 9/36), pulmonary embolism (6.7 %, n = 1 vs 0), myocardial infarction (6.7 %, n = 1 vs 2.6 %, n = 1/38) and pneumothorax (13.3 %, n = 2 vs 2.6 %, n = 1/38) were not different between two groups (p = 0.7, p = 0.3, p = 0.5 and p = 0.2). In multivariable analysis only cHIS score was associated with high mortality (p = 0.018, OR:2.8, [95 % confidence interval: 1.2–6.6]). In survival analysis, mortality rate was significantly lower in combination arm than control group (Log-Rank:p = 0.04). Combination therapy of high-dose anakinra and baricitinib may be an adequate treatment option in patients with COVID-19 who had critical disease and has acceptable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
伊绵好完成签到,获得积分10
13秒前
彩色德天发布了新的文献求助10
14秒前
14秒前
个性紫完成签到 ,获得积分10
16秒前
17秒前
超威蓝猫发布了新的文献求助10
18秒前
米线儿发布了新的文献求助10
20秒前
20秒前
lf发布了新的文献求助10
21秒前
彩色德天完成签到,获得积分10
22秒前
翻译度完成签到,获得积分10
24秒前
细水长流发布了新的文献求助20
26秒前
yingying完成签到,获得积分10
30秒前
31秒前
量子星尘发布了新的文献求助10
34秒前
大方大船完成签到,获得积分10
50秒前
谦让幻珊发布了新的文献求助10
51秒前
温柔灵波完成签到 ,获得积分10
52秒前
田様应助科研通管家采纳,获得10
55秒前
李爱国应助科研通管家采纳,获得10
55秒前
55秒前
56秒前
可爱的函函应助谦让幻珊采纳,获得10
57秒前
ding应助江洋大盗采纳,获得10
1分钟前
Song完成签到 ,获得积分10
1分钟前
谦让幻珊完成签到,获得积分10
1分钟前
嗨好发布了新的文献求助20
1分钟前
1分钟前
沈惠映完成签到 ,获得积分10
1分钟前
1分钟前
嗨好完成签到,获得积分10
1分钟前
Isaac完成签到 ,获得积分10
1分钟前
莹yy完成签到 ,获得积分10
1分钟前
乐正亦寒完成签到 ,获得积分10
1分钟前
斯文败类应助haha采纳,获得10
1分钟前
Swear完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
JingjingYao发布了新的文献求助10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976619
求助须知:如何正确求助?哪些是违规求助? 3520720
关于积分的说明 11204567
捐赠科研通 3257359
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806613